Close menu




July 20th, 2021 | 11:28 CEST

Mineworx Technologies, Siemens, Bayer - Innovation is the trump card

  • Investments
Photo credits: mineworx.net

Since 2005, the Boston Consulting Group has annually selected the world's 50 most innovative companies. The list reads like a "Who's Who" of international heavyweights: Apple, Alphabet, Amazon, Microsoft and Tesla took the top 5 spots in 2021. In total, the United States was able to occupy 26 of the 50 spots - that is an impressive number. But German companies also find their way into the illustrious circle 9 times, including Siemens and Bayer. Why is innovation so important? Innovation is a key success factor for a company to achieve above-average results and differentiate itself from competitors. For this reason, we take a closer look at innovative companies in different industries. Who is your favorite?

time to read: 2 minutes | Author: Carsten Mainitz
ISIN: MINEWORX TECHNOLOGIES LTD | CA6034652041 , SIEMENS AG NA O.N. | DE0007236101 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:


    MINEWORX TECHNOLOGIES LTD - Innovative recycling process

    The Canadians specialize in the circular economy in the mining, electronic scrap and automotive catalytic converter sectors. Mineworx has developed an innovative and patented process for recycling diesel catalysts and is now taking the next steps towards commercialization. The Company is addressing a market with more than 100 million catalysts worldwide. Around 80% of the world's production of palladium is used for catalytic converters. Palladium and platinum prices are significantly higher than gold.

    Mineworx's process does not take the conventional smelting route but instead extracts platinum and palladium specifically from ground core materials of the catalysts and through a chemical process. The Company's thoroughly planned and fully financed pilot plant is expected to be operational by the beginning of the current year's third quarter and generate initial revenues by the end of 2021. The resulting concentrate will then be sold to a refinery. The Canadians' collaboration partner for commercialization is Davis Recycling. The Company is active in 13 US states and has been recycling catalysts for 20 years. If initial production is successful, plants are planned throughout North America.

    Recently, Mineworx and Davis Recycling formed a joint venture, PGM Renewal LLC, with Mineworx holding a 55% interest and Davis a 45% interest. Mineworx will contribute its technologies and processes, according to the joint venture agreement, and Davis will be responsible for supply chain management and material preparation for the diesel catalysts. Profits generated from platinum and palladium recovery from the used diesel catalysts will be shared among the partners in proportion to their respective shareholdings.

    The commercialization of the diesel catalyst recycling business in the US could easily lead to a revaluation of Mineworx Technologies if the business takes off well. Currently, the Company is valued at only CAD 31 million.

    SIEMENS AG - Focused to grow faster

    The new Siemens CEO, Roland Busch, has formulated ambitious goals for the technology group in the medium term. Following many years of restructuring and the spin-off of units such as Infineon and Osram or the completed spin-off of the energy or medical technology business, the Group is now focusing on a new core business that is strongly linked to the area of digitalization.

    Software, automation and digital infrastructure are core elements to grow faster than the industry in the future. "Our growth drivers are digitalization, automation and sustainability. In this context, our core business and our digital business are mutually reinforcing," Busch said. Shareholders are also set to benefit from a share buyback program of up to EUR 3 billion by 2026 and a rising dividend. At prices around EUR 125, the Bavarians are valued at EUR 107 billion.

    BAYER - A long tradition

    Bayer is a life science company with a history of more than 150 years. The Group's core competencies are in the fields of health care and agriculture. The approach is to deliver products and services for a growing and aging population with the central areas of health and nutrition. The Company focuses its research and development activities on improving people's quality of life by preventing, alleviating and curing diseases. The spectrum of its business activities thus extends far beyond Covid, which is currently the subject of widespread media coverage, with its partnership with CureVac. Currently, the DAX-listed Company is valued at EUR 48 billion at prices around EUR 49.


    Innovation is a central cornerstone for the economic success of a company. Sooner or later, this is also reflected in the share price. Siemens and Bayer are suitable investments for more conservative investors, while Mineworx Technologies is suited to more risk-averse investors. The share of Mineworx Technologies could be on the verge of a revaluation.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET

    Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power

    • Digitization
    • Commodities
    • Investments

    The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Stefan Feulner on November 29th, 2022 | 13:32 CET

    Nvidia, Meta Materials, SFC Energy - Strong signs

    • Technology
    • Investments
    • nanotechnology

    After turbulent months on the technology stock markets with high markdowns, a bottoming out is taking place across the board. While many companies are reporting better-than-expected figures, investors are also buying oversold companies whose quarterly figures were below analysts' consensus. Due to the still high fluctuation range, high trading profits can be expected.

    Read